Navigation Links
Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th
Date:7/3/2009

SAN FRANCISCO, July 3 /PRNewswire-USNewswire/ -- Tomorrow, Corey Reich, an ALS patient from Piedmont, California, will attend both the San Francisco Giants and Los Angeles Angels of Anaheim baseball games this July 4th as a representative of the ALS Therapy Development Institute (ALS TDI). Corey will attend both baseball games to raise awareness of amyotrophic lateral scleroses (ALS, Lou Gehrig's disease) a neurodegenerative disease of which he suffers and for which there is no known cause or cure.

"My hope is that my presence at both games will help to put a new face on this disease by providing a personal connection to ALS," said Corey. "Although it is an orphan disease, I hope to bring larger public awareness and increased funding for research, which could speed up the discovery of therapies for people like me living with ALS."

Corey was diagnosed in July of 2007, but he had shown symptoms for several years prior. After his diagnosis, he returned to Middlebury College and graduated with honors in May of 2008. He currently is the assistant tennis coach for the Piedmont High School Men's and Women's Tennis Teams. Corey and his family have supported ALS TDI for the past 18 months and have raised more than $700,000 in that time. Fundraising events organized by "Corey's Crusaders" have included a cocktail party in the Vancouver, Washington area, a running race in Boise, a bake sale in Oakland, a dinner and dance also in Oakland, and another dinner and dance in Bronxville, New York. ALS TDI, based in Cambridge, Massachusetts, is a 501c3 nonprofit charitable organization and the largest research center dedicated solely to the development of therapeutics for this debilitating disease.

Corey's attendance at the Giants' and Angels' games coincides with the culmination of Major League Baseball's "4ALS Awareness" campaign. MLB is working with four leading organizations -- The ALS Association, AL
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encision Enters Into Sales Representation Agreement With Caldera Medical
2. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. CMR Institute: Education Key to Physician/Representative Relationship
5. Microfluidic Systems to Show Automated Biological Agent Detection Technology to U.S. House of Representatives
6. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
7. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
8. ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
11. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  US-Australian drug discovery company, Novogen ... confirmed its comprehensive scientific review has identified high ... areas of unmet patient need. Novogen is moving ... projects prior to entering into Phase 1 clinical ... Acting Chief Executive Officer, Iain Ross , ...
(Date:8/31/2015)... Grove, IL (PRWEB) , ... August 31, 2015 ... ... impurities (PGIs), as a high priority in the drug development approval process. Thus, ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ) ... USA BioSimilar Market Analysis to 2021" report to ... market will be initiated in September as Sandoz launches ... global market react? Will biosimilars explode into the biologics ... US economy up to $250 billion within the next ...
(Date:8/28/2015)... ... 28, 2015 , ... Riordan-McKenna Institute founders, stem ... that the use of sterile, dehydrated amniotic tissue AlphaPATCHâ„¢ developed by Amniotic ... surgical knee wound. , The case involved a 78-year-old male, who presented with ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... June 24 The Board of,Directors of Schering-Plough Corporation ... 6.5 cents per common share. Payment will be made ... close of business on Aug.,1, 2008. As of March ... Board of Directors today also declared a quarterly dividend ...
... Sun Pharmaceutical,Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: ... Levitt, Chairman of the Board,of Directors of Taro Pharmaceutical ... Levitt,s letter of June 19, 2008 to Taro,s,shareholders, his ... the Initiating,Motion filed by Taro in the Tel-Aviv District ...
... etiquette tips via live, interactive ... ... a new way for life science post graduates to enhance their skills,and ... a dual-purpose service that,provides employers a chance to meet potential candidates, and ...
Cached Biology Technology:Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 2Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 3Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 5Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 6Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 7Online Career Tool Offers Live 'Expert Advice' Component 2
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... has comparable efficacy to chemotherapy, and is better ... has progressed quickly after treatment with first-line therapy, ... show. Dr Tudor Ciuleanu from the Institute ... finding from the international TITAN study at the ...
... have found that when growing corn crops for ethanol, more ... edition of the American Chemical Society,s journal Environmental Science ... fertilizer while they improve their production of feedstock for ethanol ... implications for an industry that has grown dramatically in recent ...
... York University,s Clinical and Translational Science Institute (CTSI) has ... grant to assess the feasibility of using gingival crevicular ... a blood glucose measurement -- as a means of ... between New York University,s Langone Medical Center and the ...
Cached Biology News:Erlotinib effective and with fewer side-effects after first-line treatment 2Overfertilizing corn undermines ethanol 2Overfertilizing corn undermines ethanol 3NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique 2NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique 3